132 related articles for article (PubMed ID: 36539356)
21. Subgroup analysis by prior anti-VEGF or anti-EGFR target therapy in FRESCO, a randomized, double-blind, Phase III trial.
Xu R; Qin S; Guo W; Bai Y; Deng Y; Yang L; Chen Z; Zhong H; Pan H; Shu Y; Yuan Y; Zhou J; Xu N; Liu T; Ma D; Wu C; Cheng Y; Xu J; Chen D; Li W; Sun S; Yu Z; Cao P; Li J; Chen H; Wang J; Wang S; Wang H; Wang N; Zhang B; Han R; Su W; Guo X; Li J
Future Oncol; 2021 Apr; 17(11):1339-1350. PubMed ID: 33325251
[TBL] [Abstract][Full Text] [Related]
22. A multi-center effectiveness comparison study of fruquintinib with constructed external control cohort of other targeted kinase inhibitors using real-world data in third-line treatment of metastatic colorectal cancer.
Jin Y; Li J; Shen L; Xu J; Zhang Y; Zhang J; Pan H; Qu X; Chen Y; Zhang Q; Li J; Sun M; Qin S
Front Oncol; 2022; 12():1044328. PubMed ID: 36505849
[TBL] [Abstract][Full Text] [Related]
23. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043).
Sleijfer S; Ray-Coquard I; Papai Z; Le Cesne A; Scurr M; Schöffski P; Collin F; Pandite L; Marreaud S; De Brauwer A; van Glabbeke M; Verweij J; Blay JY
J Clin Oncol; 2009 Jul; 27(19):3126-32. PubMed ID: 19451427
[TBL] [Abstract][Full Text] [Related]
24. Fruquintinib in Combination With PD-1 Inhibitors in Patients With Refractory Non-MSI-H/pMMR Metastatic Colorectal Cancer: A Real-World Study in China.
Gou M; Qian N; Zhang Y; Yan H; Si H; Wang Z; Dai G
Front Oncol; 2022; 12():851756. PubMed ID: 35875064
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and Safety Comparison of Regorafenib and Fruquintinib in Metastatic Colorectal Cancer-An Observational Cohort Study in the Real World.
Zhang Q; Chen M; Wang Z; Qi C; Cao Y; Zhang J; Peng Z; Wang X; Lu M; Shen L; Li J
Clin Colorectal Cancer; 2022 Sep; 21(3):e152-e161. PubMed ID: 35216918
[TBL] [Abstract][Full Text] [Related]
26. Comparison of efficacy and toxicity of first line chemotherapy with or without epirubicin for patients with advanced stage soft tissue sarcoma.
Cao J; Huang XE; Liu J; Wu XY; Lu YY
Asian Pac J Cancer Prev; 2013; 14(12):7171-7. PubMed ID: 24460271
[TBL] [Abstract][Full Text] [Related]
27. Randomised phase 2 study comparing the efficacy and safety of the oral tyrosine kinase inhibitor nintedanib with single agent ifosfamide in patients with advanced, inoperable, metastatic soft tissue sarcoma after failure of first-line chemotherapy: EORTC-1506-STBSG "ANITA".
Schöffski P; Toulmonde M; Estival A; Marquina G; Dudzisz-Śledź M; Brahmi M; Steeghs N; Karavasilis V; de Haan J; Wozniak A; Cousin S; Domènech M; Bovée JVMG; Charon-Barra C; Marreaud S; Litière S; De Meulemeester L; Olungu C; Gelderblom H
Eur J Cancer; 2021 Jul; 152():26-40. PubMed ID: 34062484
[TBL] [Abstract][Full Text] [Related]
28. Real-World Outcomes of Pazopanib Treatment in Korean Patients with Advanced Soft Tissue Sarcoma: A Multicenter Retrospective Cohort Study.
Oh CR; Hong JY; Kim JH; Lee JS; Kim HS; Kim TW; Ahn JH; Kim JE
Target Oncol; 2020 Aug; 15(4):485-493. PubMed ID: 32607656
[TBL] [Abstract][Full Text] [Related]
29. [Clinical efficacy and safety of apatinib combined with chemotherapy for osteosarcoma and soft tissue sarcoma with pulmonary metastasis].
Li SL; Yang QK; Chen P; Zheng K; Wang W; Pei Y; Zhang XJ
Zhonghua Zhong Liu Za Zhi; 2019 Apr; 41(4):309-314. PubMed ID: 31014058
[No Abstract] [Full Text] [Related]
30. Efficacy and safety of apatinib in patients with untreated or chemotherapy-refractory soft tissue sarcoma: a multicenter, phase 2 trial.
Yu W; Zhang H; Chen J; Zhang X; Chen Y; Qu G; Huang G; Zhou Y; Ye T; Fan Z; Yao Y
Ann Transl Med; 2022 Sep; 10(18):981. PubMed ID: 36267741
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of apatinib as third- or further-line therapy for patients with advanced NSCLC: a retrospective study.
Liang J; Gu W; Jin J; Zhang H; Chen Z; Tang Y; Zhang S; Yang S; Deng Y; Feng W
Ther Adv Med Oncol; 2020; 12():1758835920968472. PubMed ID: 33403012
[TBL] [Abstract][Full Text] [Related]
32. Phase II trial of ifosfamide in combination with the VEGFR inhibitor sorafenib in advanced soft tissue sarcoma: a Spanish group for research on sarcomas (GEIS) study.
García Del Muro X; Maurel J; Martínez Trufero J; Lavernia J; López Pousa A; de Las Peñas R; Cubedo R; Berros JP; Casado Herráez A; de Juan A; Martín Broto J
Invest New Drugs; 2018 Jun; 36(3):468-475. PubMed ID: 29527631
[TBL] [Abstract][Full Text] [Related]
33. Phase 1b/2 trial of fruquintinib plus sintilimab in treating advanced solid tumours: The dose-escalation and metastatic colorectal cancer cohort in the dose-expansion phases.
Guo Y; Zhang W; Ying J; Zhang Y; Pan Y; Qiu W; Fan Q; Xu Q; Ma Y; Wang G; Guo J; Su W; Fan S; Tan P; Wang Y; Luo Y; Zhou H; Li J
Eur J Cancer; 2023 Mar; 181():26-37. PubMed ID: 36628898
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and Safety of Regorafenib Combined with Toripalimab in the Third-Line and beyond Treatment of Advanced Colorectal Cancer.
Yu W; Tao Q; Zhang Y; Yi F; Feng L
J Oncol; 2021; 2021():9959946. PubMed ID: 34603452
[TBL] [Abstract][Full Text] [Related]
35. First-line anthracycline-based chemotherapy for angiosarcoma and other soft tissue sarcoma subtypes: pooled analysis of eleven European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group trials.
Young RJ; Natukunda A; Litière S; Woll PJ; Wardelmann E; van der Graaf WT
Eur J Cancer; 2014 Dec; 50(18):3178-86. PubMed ID: 25459395
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of regorafenib as beyond second-line therapy in patients with metastatic colorectal cancer: an adjusted indirect meta-analysis and systematic review.
Wu Y; Fan Y; Dong D; Dong X; Hu Y; Shi Y; Jing J; Li E
Ther Adv Med Oncol; 2020; 12():1758835920940932. PubMed ID: 32728393
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of regorafenib and fruquintinib as third-line treatment for colorectal cancer: a narrative review.
Xu X; Yu Y; Liu M; Liang L; Liu T
Transl Cancer Res; 2022 Jan; 11(1):276-287. PubMed ID: 35261903
[TBL] [Abstract][Full Text] [Related]
38. Phase Ib/II Study of the Safety and Efficacy of Combination Therapy with Multikinase VEGF Inhibitor Pazopanib and MEK Inhibitor Trametinib In Advanced Soft Tissue Sarcoma.
Subbiah V; Meyer C; Zinner R; Meric-Bernstam F; Zahurak ML; O'Connor A; Roszik J; Shaw K; Ludwig JA; Kurzrock R; Azad NA
Clin Cancer Res; 2017 Aug; 23(15):4027-4034. PubMed ID: 28377484
[No Abstract] [Full Text] [Related]
39. Outcomes of Elderly Patients with Advanced Soft Tissue Sarcoma Treated with First-Line Chemotherapy: A Pooled Analysis of 12 EORTC Soft Tissue and Bone Sarcoma Group Trials.
Younger E; Litière S; Le Cesne A; Mir O; Gelderblom H; Italiano A; Marreaud S; Jones RL; Gronchi A; van der Graaf WTA
Oncologist; 2018 Oct; 23(10):1250-1259. PubMed ID: 29650688
[TBL] [Abstract][Full Text] [Related]
40. Large Scale, Multicenter, Prospective Study of Apatinib in Advanced Gastric Cancer: A Real-World Study from China.
Peng W; Zhang F; Wang Z; Li D; He Y; Ning Z; Sheng L; Wang J; Xia X; Yu C; Wang Z; Zhao Y; Liang H; Hu B; Sun C; Wang D; Cheng Y; Pan M; Xia L; Guo X; Zhang Y; Hu Z; Li X; Lu L; Zhang J; Qian H; Xie H; Sun G
Cancer Manag Res; 2020; 12():6977-6985. PubMed ID: 32821164
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
